Targeting BCMA in Multiple Myeloma

[1] Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30

[2] Miller KD(2017)Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial Lancet 389 519-527

[3] Jemal A(2008)Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516-2520

[4] Durie BG(2018)Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial Leukemia 32 383-390

[5] Hoering A(2020)Emerging immunotherapies in multiple myeloma BMJ 370 m3176-2275

[6] Abidi MH(2019)Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy Leukemia 33 2266-874

[7] Rajkumar SV(2004)Clinical course of patients with relapsed multiple myeloma Mayo Clin Proc 79 867-1702

[8] Epstein J(1998)The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily Int Immunol 10 1693-738

[9] Kahanic SP(2012)Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival Br J Haematol 158 727-1199

[10] Kumar SK(2015)Targeting B-cell maturation antigen in multiple myeloma Immunotherapy 7 1187-694

[1] Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30

[2] Miller KD(2017)Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial Lancet 389 519-527

[3] Jemal A(2008)Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516-2520

[4] Durie BG(2018)Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial Leukemia 32 383-390

[5] Hoering A(2020)Emerging immunotherapies in multiple myeloma BMJ 370 m3176-2275

[6] Abidi MH(2019)Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy Leukemia 33 2266-874

[7] Rajkumar SV(2004)Clinical course of patients with relapsed multiple myeloma Mayo Clin Proc 79 867-1702

[8] Epstein J(1998)The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily Int Immunol 10 1693-738

[9] Kahanic SP(2012)Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival Br J Haematol 158 727-1199

[10] Kumar SK(2015)Targeting B-cell maturation antigen in multiple myeloma Immunotherapy 7 1187-694